Results
sore throat, feverishness, upper respiratory tract symptoms, cough
ADVERSE REACTIONS, SORE THROAT, ADVERSE EVENTS, COVID-19 INFECTION, RVF
Between 2ChAdOx1 RVF was determined to have an acceptable safety and tolerability profile during interim safety reviews, allowing dose-escalation to proceed as planned. No serious adverse events occurring in any of the participants following vaccination. Mild local reactions were common, with 14 of the 15 participants reporting solicited local adverse reactions (No participants in the low dose group reported any systemic solicited adverse events. However, 4 of the 6 participants in the intermediate dose group and all participants in the high dose group reported systemic symptoms that were mostly mild in intensity (All unsolicited adverse events reported within 28 days of vaccination were either mild or moderate in severity and are detailed within (Mild COVID-19 occurred in 2 participants within 28 days of vaccination, both in the high dose group. The first of these tested positive on a COVID-19 lateral flow device following mild feverishness on day 1 post-vaccination. Their symptoms resolved by day 2 and they were otherwise well. The second volunteer tested positive for COVID-19 after experiencing mild to moderate upper respiratory tract symptoms (sore throat, sneezing, cough) at day 20 which resolved by day 27. Neither of their immune responses to RVFV Gn and Gc was remarkable in comparison to other participants and it is unclear how, if at all, their COVID-19 infections impacted upon this.Laboratory adverse events are described in ChAdOx1 RVF was highly immunogenic, with 12 of the 15 vaccinees mounting a detectable RVF nAb response that peaked at day 28 post-vaccination and persisted to the final follow-up visit at day 84 (